Revenio Group Corporation: Expanding Applications for AI-Assisted iCare ILLUME Screening Solution
In addition to diabetic retinopathy, the AI-assisted iCare ILLUME screening has also been extended to screen for age-related macular degeneration and glaucoma. This solution supports early detection of increasingly common eye diseases.
The iCare ILLUME screening solution uses artificial intelligence to instantly detect signs of vision-threatening disease. The solution has received excellent market feedback and will be introduced in spring 2022 to screen for diabetic retinopathy. He can now screen for three common eye diseases: diabetic retinopathy, age-related macular degeneration, and glaucoma.
Age-related eye diseases are becoming more common worldwide. iCare ILLUME screening solutions help detect eye disease early, speeding initiation of treatment. The solution is easy to use, highly accurate, and fully automated. The severity of eye disease can be found on the screening report. Screening solutions have been developed to be more flexible regarding the number of ophthalmic images and fields of use. This solution is currently available in 11 languages.
The iCare ILLUME screening solution supports clinical decision-making in ophthalmic disease. Accurate data generated by iCare imaging devices and associated software is at the core of the solution. iCare ILLUME combines artificial intelligence with images captured by the iCare DRSplus Retinal Imaging System for instant screening reports. Patients in need can then be digitally referred for re-examination by an ophthalmologist. This allows for more extensive use of the high-quality images produced by retinal imaging devices to increase the efficiency of the treatment process.
A comprehensive iCare solution includes digital tools to enhance and improve the quality of eye care while enabling diagnosis and treatment of more patients. With digital tools that connect your eye care pathway, you can increase productivity while delivering high quality care at the same time.
Pirjo Korttesto, Business Line Director of Icare Finland, commented: “Ocular diseases associated with an aging population are becoming more common worldwide, requiring innovative solutions to increase the efficiency of eye disease screening and prevent visual impairment. Our software solutions are playing an increasingly important role in the eye care pathway.”
More information on iCare ILLUME screening solutions can be found on our website https://www.icare-world.com/product/icare-illume/.
Contact us for more information
Pirjo Korttesto, Business Line Director, Screening Division
pirjo.korttesto@icare-world.com
distribution
major media
www.reveniogroup.fi/en
Overview of the Revenio Group
Revenio is a leading player in the global market for ophthalmic equipment and software solutions. Revenio’s ophthalmic diagnostic solutions include intraocular pressure (IOP) measurement devices (tonometers), fundus imaging devices, perimeters, as well as iCare branded clinical software. iCare is your trusted partner in ophthalmic diagnostics, providing physicians with fast, easy-to-use, and reliable tools for diagnosing glaucoma, diabetic retinopathy, and macular degeneration (AMD). iCare solutions provide digital clinical tools that increase efficiency and improve quality in eye care.
In 2022, the Group’s net sales totaled €97 million and operating profit was €29.7 million. Revenio Group Corporation is listed on the Nasdaq Helsinki under the trading code REG1V.
iCare overview
iCare is a Finnish company that develops and manufactures innovative handheld tonometers, fundus imagers, perimeters and software solutions for the diagnosis and screening of eye diseases. iCare’s vision is to make the world visible to all, and its goal is to advance the identification and treatment of eye diseases through technology solutions. iCare’s products are reliable, efficient, and easy to use, enabling early and accurate diagnosis. iCare works with industry experts to continuously develop new solutions to promote eye health. iCare is part of the Revenio Group Corporation, listed on the Helsinki Stock Exchange.
